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Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life-threatening complica-
tion affecting patients undergoing hematopoietic stem cell transplantation (HSCT). The survival rate is higher when
specific therapy is initiated early; thus, improving early, noninvasive diagnosis of VOD/SOS is an important need. In
an adult population undergoing HSCT, we aimed to assess the role of liver stiffness measurement (LSM), evaluated
by transient elastography (TE), for diagnosing VOD/SOS. Between April 2016 and March 2018, 78 consecutive adult
patients with indications for allogeneic HSCT were prospectively included. LSM was performed before HSCT and at
days +9/10, +15/17, and +22/24 post-HSCT. New European Society for Blood and Marrow Transplantation criteria
were used to establish VOD/SOS diagnosis. Four patients developed VOD/SOS (5.1%) during the study period, with a
median time of +17 days post-HSCT. A sudden increase in LSM compared with previously assessed values and pre-
HSCT values, was seen in all patients who developed VOD/SOS. LSM increases occurred from 2 to 12 days before
clinical SOS/VOD appearance. The VOD/SOS diagnostic performance of increased LSM over pre-HSCT assessment
showed an area under the receiver operating characteristic curve of 0.997 (sensitivity 75%; specificity 98.7%).
LSM gradually decreased following successful VOD/SOS-specific treatment. Interestingly, LSM values did not
increase significantly in patients experiencing hepatobiliary complications (according to the Common Terminology
Criteria) other than VOD/SOS. LSM by TE can be considered a promising method to perform an early, preclinical
diagnosis and follow-up of VOD/SOS.
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Veno-occlusive disease (VOD), also known as sinusoidal
obstruction syndrome (SOS), is a relatively rare but potentially
life-threatening complication that can affect patients after
hematopoietic stem cell transplantation (HSCT) [1]. It occurs in
roughly 14% (5% to 60%) of patients after HSCT [2], depending
on several known factors [1,35]. From a pathophysiological
standpoint, conditioning regimens can cause a toxic injury insinusoidal endothelial cells, with consequent damage of
hepatic acini and blood outflow blockage, causing sinusoidal
portal hypertension (PH) [3,6,7]. Clinical signs such as ascites,
weight gain, painful hepatomegaly, and jaundice, which are
the clinical diagnostic criteria for VOD/SOS [811], are directly
connected to PH. These clinical criteria are crucial to establish-
ing a diagnosis of VOD/SOS. Several conditions can mimic or
overlap VOD/SOS, (eg, cholangitis, bacterial sepsis, acute graft-
versus-host disease [GVHD], biliary sludge), and histological
confirmation is often needed to accurately discriminate among
multiple differential diagnoses [12]. Moreover, severe forms of
VOD/SOS frequently lead to severe multiorgan dysfunction/
failure (MOD/MOF) [3], with reported mortality of up to 80%
rate in a historical cohort [13]. However, it has been demon-
strated that an early and prompt diagnosis, leading to earlier
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improved day +100 survival in patients with MOF and in those
without MOD [15,16]. For this reason, the recognition of VOD/
SOS in its milder forms or at earlier stages [17] is highly impor-
tant. New ultrasonography scores and technological ultra-
sound improvement may help to confirm the diagnosis in
suspected VOD/SOS [1820]; however, early recognition of
VOD/SOS remains a challenge. Invasive methods, such as the
measurement of hepatic vein pressure gradient (HVPG) and
transjugular liver biopsy, can lead to a conclusive diagnosis of
VOD/SOS with high specificity, although their use may be lim-
ited in selected cases and in well-trained centers [12].
Recently, ultrasound elastography techniques to perform
liver stiffness measurement (LSM) have been investigated as a
possible surrogate for PH and its complications [2124]. Studies
and meta-analyses have confirmed the close relationship
between LSM and HVPG, the gold standard for evaluating PH, in
patients with advanced chronic liver disease (ACLD) [2527].
To date, among these techniques, only transient elastog-
raphy (TE) [2830] and point-shear wave elastography by
acoustic radiation force impulse imaging [29,31] have been
evaluated for assessment of liver complications in pediatric
patients undergoing HSCT. No study has yet been reported
on the role of LSM in VOD/SOS assessment in the setting of
adult HSCT. Here we report the results of a monocentric pro-
spective study evaluating the role of LSM as assessed by TE in
the development of VOD/SOS in adult patients undergoing
allogeneic HSCT for hematologic malignancies.
METHODS
Patients and Study Design
This monocentric prospective study included consecutive adult patients
undergoing allogeneic HSCT at the Institute of Hematology L. and A. Serag-
noli, Sant'Orsola-Malpighi University Hospital, Bologna, Italy between April
2016 and March 2018. The inclusion criteria were allogeneic HSCT from any
type of donor and hematopoietic stem cell source with either myeloablative
and reduced-intensity conditioning, hematologic indication for allogeneic
HSCT, and age 18 to 70 years. The exclusion criteria were body mass index
(BMI) >40 kg/m2 with ascites and the presence of ACLD at pre-HSCT assess-
ment, to avoid possible technical LSM bias.
The primary objective was to investigate the clinical role of LSM in the
development of VOD/SOS in the setting of adult allogeneic HSCT as assessed
by TE. Secondary objectives included assessing the predictive factors associ-
ated with VOD/SOS diagnosis, evaluating the role of LSM in follow-up man-
agement of VOD/SOS, comparing the application of LSM and ultrasound in
assessment of VOD/SOS, and defining the role of LSM in the differential diag-
nosis among other liver-related complications of HSCT.
The study protocol included clinical evaluation, biochemical assays, gray-
scale and color Doppler ultrasound, and LSM evaluation of all patients
included at enrollment (within 1 month before HSCT). Subsequent LSM eval-
uations were done on a dense assessment schedule on days +9/10 (T1), +15/
17 (T2), and +22/24 (T3) after HSCT, 3 days/week assessment of biochemical
laboratory tests, and a daily clinical assessment of the presence of VOD/SOS
criteria from the initiation of the conditioning regimen until 30 days after
HSCT. In cases of clinical suspicion of VOD/SOS according to the European
Society for Blood and Marrow Transplantation (EBMT) criteria [8], in the
interval between 2 subsequent scheduled time points (T0-T1, T1-T2, T2-T3,
or >T3), in addition to the foregoing study protocol, color Doppler ultra-
sound, LSM, and intensive clinical monitoring were carried out based on the
seriousness of the clinical features. If increased LSM values were found at any
scheduled time point, color Doppler ultrasound, biochemical testing, and
intensive clinical monitoring were further assessed to confirm/exclude the
diagnosis, according to the EBMT recommendations. When VOD/SOS was
diagnosed, weekly LSM evaluations were performed until clinical VOD/SOS
was resolved.
This trial was conducted in compliance with the Declaration of Helsinki
and was approved by the Institutional Ethics Committee of Sant'Orsola-Mal-
pighi University Hospital (protocol 125/2015/O/Sper). Written informed con-
sent was obtained from each patient.
VOD/SOD Diagnosis
VOD/SOS of the liver was defined by EBMT clinical diagnostic criteria [8].
Accordingly, painful hepatomegaly, weight gain, and serum bilirubin2.0 mg/dL with or without ultrasound signs (only in late VOD) were consid-
ered typical clinical signs for VOD/SOS diagnosis; in doubtful cases, further
invasive diagnostic analyses (liver biopsy and HVPG) were performed to con-
firm the clinical diagnosis. VOD/SOS grading was defined in accordance with
EBMT criteria for severity grading [8]. VODwith MOF was defined as the pres-
ence of renal and/or pulmonary dysfunction in addition to VOD.
Other Hepatobiliary Complications
The occurrence of other hepatobiliary complications after HSCT, such as
hepatic GVHD, infective hepatobiliary diseases, and other drug-induced liver
injury (DILI) in accordance with clinical definitions [3235], were also evalu-
ated. Patients with liver biochemical alterations were stratified based on the
Common Terminology Criteria for Adverse Events version 4 (CTC) [36].
Liver Stiffness Measurement (LSM)
LSM values were assessed at the patients’ bedside by TE using the Fibro-
Scan apparatus with an “M” probe (Echosens, Paris, France) after an overnight
fast and after a complete abdominal ultrasound examination. LSM values
were obtained as described previously [37]. The reliability criteria were con-
sidered in accordance with the latest European Federation of Societies for
Ultrasound in Medicine and Biology's guidelines and recommendations on
the clinical use of ultrasound elastography [38]; the reliability criterion was
at least 10 measurements with a ratio of the interquartile range (IQR) of liver
stiffness to the median (IQR/M) 30%.
Abdominal Ultrasound
All patients underwent baseline gray-scale and color Doppler ultrasound
examinations before HSCT, when LSM increased and in case of the presence
of one among the VOD/SOS clinical signs criteria [8] in the interval between
scheduled time points. Ultrasound findings were evaluated according to the
Lassau criteria [18]. During hospitalization, ultrasound examinations were
performed at the bedside with a Noblus with a UST-9147 convex ultrasound
transducer (Hitachi Medical, Tokyo, Japan).
Supportive Care
Patients were allocated in single positive-pressure rooms with HEPA-
filtered air. Anti-infectious prophylaxis was administered according to the
local practice, with levofloxacin and antifungal drugs (fluconazole for HLA-
identical sibling transplant and voriconazole for all other transplants) during
the neutropenic phase. All patients received acyclovir and cotrimoxazole on a
standard schedule until 9 months after HSCT or throughout the duration of
immunosuppression.
CMV and EBV monitoring was performed once or twice weekly, depend-
ing on the risk of the pairs during the first 100 days after transplantation,
and once a month thereafter. All patients received filtered and irradiated
blood products.
Data Management and Statistical Analysis
Data were collected and managed using REDCap electronic data cap-
ture tools hosted at Department of Medical and Surgical Sciences, Univer-
sity of Bologna [39]. Categorical data are expressed as number
(percentage) and continuous variables are expressed as median and IQR.
For group comparisons, the Wilcoxon signed-rank test was used for con-
tinuous variables, and the Fisher exact test was used for categorical varia-
bles. Univariate logistic regression analyses were performed to evaluate
predictors of VOD/SOS development after HSCT. A receiver operating char-
acteristic curve was created to calculate the area under the curve (AUC) for
LSM changes over pre-HSCT assessment. All P values are 2-tailed.
Statistical analyses were performed using Stata/SE version 14.2 for Win-
dows (StataCorp, College Station, TX).
RESULTS
Over the study period, of the 89 patients referred to the
transplantation center, 2 were excluded because of BMI >40
and ACLD at enrollment, and 9 did not undergo HSCT (due to
donor unavailability or disease progression) after being
enrolled initially. As shown in Figure 1, 78 patients met all the
inclusion criteria and underwent HSCT. During the study
period, 2 patients were transferred to an intensive care unit,
and 4 patients died from non-liver-related causes. One patient
died from severe VOD/SOS.
The clinical and transplantation characteristics of the
enrolled patients are summarized in Table 1 and Table 2,
respectively. Before HSCT, almost all patients (92.3%) received
blood transfusions (median serum ferritin level, 738 ng/mL
[IQR, 68 to 1333 ng/mL]), and 32 patients (41.1%) received
Figure 1. Flow chart of the enrolled patients.
Table 1
Baseline Characteristics of Study Population and by VOD/SOS Diagnosis
Characteristic Study population (N = 78) Without VOD/SOS (n = 74; 94.9%) With VOD/SOS (n = 4; 5.1%) P Value*
Male sex, n (%) 39 (50) 37 (50) 2 (50) 1
Age, yr, median (IQR) 54 (40-60) 54 (41-60) 46 (31-60) .696
BMI, kg/m2, median (IQR) 25 (22.6-27.5) 25.1 (23-27.5) 21.5 (21.1- 23.8) .358
Ethnicity .106
Caucasian 73 (93.6) 70 (94.5) 3 (75)
African/African American 3 (3.8) 3 (4.1) 0 (0)
Asiatic 2 (2.6) 1 (1.4) 1 (25)
Diagnosis, n (%) .133
Acute myelogenous leukemia 35 (44.9) 34 (45.9) 1 (25)
Acute lymphoblastic leukemia 14 (17.9) 12 (16.2) 2 (50)
Myelodysplastic syndrome 11 (14.1) 11 (14.9) 0 (0)
Hodgkin lymphoma 5 (6.4) 5 (6.8) 0 (0)
Non-Hodgkin lymphoma 4 (5.1) 4 (5.4) 0 (0)
Multiple myeloma 2 (2.6) 2 (2.7) 0 (0)
Myelofibrosis 3 (3.8) 3 (4.1) 0 (0)
Chronic myelogenous leukemia 3 (3.8) 3 (4.1) 0 (0)
Severe aplastic anemia 1 (1.3) 0 (0) 1 (25)
Blood transfusion history, n (%) .029
20 transfusions 46 (58.9) 46 (62.2) 0 (0)
>20 transfusions 32 (41.1) 28 (37.8) 4(100)
HCT-CI Sorror total score, median (IQR) 0 (0-2) 0 (0-1.5) 2 (.75-3) .247
LSM at baseline, median (IQR) 4.2 (3.8- 5.3) 4.2 (3.8-5.2) 6.9 (5.7-7.8) .079
Significant P values are in bold type.
HCT-CI indicates hematopoietic cell transplantation comorbidity index.
* Wilcoxon rank-sum test/Fisher exact test.
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Table 2
Transplantation Characteristics According to VOD/SOS Occurrence
Characteristic Study Population (N = 78) Without VOD/SOS (n = 74; 94.9%) With VOD/SOS (n = 4; 5.1%) P Value*
Conditioning regimen, n (%) .190
Myeloablative conditioning 52 (66.7) 48 (92.3) 4 (7.7)
TBI-Cy 2 (3.8) 2 (4.2) 0 (0.0) .899
TBF 47 (90.5) 45 (93.7) 2 (50) .523
Bu- Flu 2 (3.8 ) 1 (2.1) 1 (25) .004
Cy200 1 (1.9) 0 (0.0) 1 (25) .05
Reduced-intensity conditioning 26 (33.3) 26 (100) 0 (0) .190
TBF 13 (50) 13 (50) 0 (0.0) .475
TCF 13 (50) 13 (50) 0 (0.0) .475
GVHD prophylaxis, n (%)
ATLG-CNI-MTX 73 (93.6) 69 (93.2) 4 (100) .537
CNI-MTX 2 (2.6) 2 (2.7) 0 (0) .899
CNI-MMF-PT-Cy 3 (3.8) 3 (4.1) 0 (0) .852
Stem cell donor, n (%)
Matched related donor 12 (15.4) 11 (14.9) 1 (25) .495
Unrelated donory 53 (67.9) 50 (67.6) 3 (75) .616
Haploidentical donor 3 (3.8) 3 (4.1) 0 (0.0) .852
Cord blood 5 (6.4) 5 (6.7) 0 (0.0) .721
Stem cell source, n (%) .676
Peripheral blood 58 (74.4) 54 (73) 4 (100)
Bone marrow 15 (19.2) 15 (20.3) 0 (0.0)
Umbilical cord blood 5 (6.4) 5 (6.8) 0 (0.0)
Significant P values are in bold type.
TBI indicates total body irradiation; Cy, cyclophosphamide; TBF, thiotepa-busulfan-fludarabine; Bu-Flu, busulfan-fludarabine; TCF, thiotepa-cyclophosphamide-flu-
darabine; ATLG, anti-T lymphocyte globulin; CNI, calcineurin inhibitor; MTX, methotrexate; MMF, mofetil mycophenolate; PT-Cy, post-transplantation
cyclophosphamide.
* Fisher exact test.
y Thirty-four patients (64.1%) were 10/10 HLA-matched, and 19 (35.9%) were <10/10 HLA-matched.
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4.2 kPa (IQR, 3.8 to 5.3 kPa).
During the study period, 4 of 78 patients (5.1%) met the
clinical diagnostic criteria for VOD/SOS. Themedian day of clin-
ical VOD/SOS diagnosis was day +17 (IQR, day +4 to day +28)
post-HSCT. Characteristics of the patients who developed
VOD/SOS are reported in Table 3. Three of the 4 cases of VOD/
SOS were severe/very severe, and 1 case led to MOF and death
several days after onset (patient 3). These patients received a
myeloablative conditioning regimen based on busulfan or
cyclophosphamide and a greater number of pretransplantation
blood transfusions (>20) compared with the patients who did
not develop VOD/SOS (Tables 1 and 2).
Table 4 shows that among the EBMT-defined pre-HSCT risk
factors for VOD/SOS [8], these 4 patients underwent previous
therapy with inotuzumab ozogamicin (n = 3) or other hepa-
toxic drugs (n = 1), and 2 of them had pre-HSCT iron overload.
Regarding the ultrasound findings at VOD/SOS diagnosis
(Table 5), according to the Lassau criteria [18] (increased diag-
nostic likelihood when 3 criteria were met), 3 of the 4
patients met 3 gray-scale ultrasound morphological criteria
and no patients met 3 color Doppler criteria. Only portal vein
diameter >12 mm was seen in all 4 patients diagnosed with
VOD/SOS.
LSM values at each time point are reported in Figure 2. LSM
values were increased in all patients who developed VOD/SOS
(red continuous lines). The median pre-HSCT (T0) LSM values
did not differ between patients with VOD/SOS and those with-
out VOD/SOS (6.9 kPa versus 4.2 kPa; P = .079). LSM values
were increased at the assessment performed before the clinical
diagnosis of VOD/SOS, and these values were significantly dif-
ferent from those measured at T0 and at previous assessments.
In general, the LSM values showed a sudden increase from
days 2 to 12 before the clinical VOD/SOS diagnosis (Table 3).
After the initiation of treatment for VOD/SOS (defibrotide anddiuretics), LSM values decreased, reaching pretransplantation
values within 2 to 4 weeks after VOD/SOS diagnosis. One
patient, who died 20 days after being diagnosed with severe
VOD/SOS, did not exhibit decreased LSM values (Figure 3).
Logistic regression analysis demonstrated that an increase
in LSM values after HSCT over pre-HSCT assessment was signif-
icantly associated with the likelihood of diagnosis of VOD/SOS
(odds ratio, 1.837; 95% confidence interval, 1.1107 to 3.0384;
P < .001). Furthermore, receiver operating characteristic curve
analysis of LSM increases over pre-HSCT assessment revealed
an area under the curve of .997 with a sensitivity of 75% and
specificity of 98.7%. For instance, an increase of +10 kPa over
pre-LSM-HSCT assessment showed a sensitivity of 100% and
specificity of 98.7% for diagnosing VOD/SOS.
During the study period, among the 74 patients who did
not develop VOD/SOS, 62 experienced no or mild-to-moderate
therapy-associated complications without severe liver involve-
ment after HSCT (CTC grade 0 to 3). Twelve patients experi-
enced severe liver complications (CTC grade 4 to 5), including
2 with acute cholecystitis, 1 with cholangitis, 2 with DILI
related to antimycotic drug use, 1 with hepatic GVHD, 5 with
isolated liver biochemical alterations, and 1 with fulminant
Epstein-Barr virus-related hepatitis reactivation.
The median LSM values after HSCT were not significantly
different between the patients with CTC grade 0 to 3 and those
with CTC grade 4 to 5 (6.1 kPa [IQR, 5 to 6.8 kPa] versus 6.6 kPa
[IQR, 4.8 to 8.6 kPa]; P = .724); however, these values were sig-
nificantly different (P < .001) between patients with CTC grade
4 to 5 and patients with VOD/SOS (Figure 4). Regardless, only 1
patient, a 67-year-old patient with Philadelphia chromosome-
positive acute lymphoblastic leukemia, showed a sudden
increase in LSM values (13.5 kPa) in the absence of any clinical
signs of VOD/SOS (Figure 2). Over the next month, the patient
developed mildly painful hepatomegaly and a tender abdomen






























































































































































































































































































































































































































































































































A. Colecchia et al. / Biol Blood Marrow Transplant 25 (2019) 9951003 999biopsy revealed widespread dilatation of hepatic sinusoids and
the presence of atypical elements such as B lymphoblastic leu-
kemia infiltration. At this time, the patient's LSM value was 20
kPa. We believe that this case described above is an uncom-
mon clinical situation in which the infiltration of liver sinus-
oids by leukemia mimics the presence of sinusoidal
obstruction typical of the pathogenesis of VOD/SOS after HSCT.
DISCUSSION
The aim of this study was to evaluate the clinical role of
LSM values measured by TE on VOD/SOS development in a pro-
spective cohort of adult patients undergoing allogeneic HSCT.
The rationale for using LSM as an early detector of VOD/SOS is
related to its pathogenesis, with congestion from blood out-
flow block and inflammation from loss of sinusoidal wall integ-
rity by toxic injury leading to sinusoidal PH. These conditions
were previously identified as determinants of LSM increase in
PH [38].
Our data show significantly increased LSM values compared
with previous measurements and pre-HSCT measurements
only in patients who developed VOD/SOS. This allows for a pre-
clinical diagnosis because the sudden increase in stiffness
anticipated the standard EBMT-based clinical diagnosis by 2 to
12 days (Figure 2).
In our study population, the incidence of VOD/SOS was
5.1%, with a 3.8% rate of severe disease, in line with the cur-
rent reports in adult cohorts [40,41]. As expected, VOD/SOS
occurred mostly in patients with a higher number of VOD/
SOS risk factors according to the latest EBMT classification
scheme [8]. Indeed, in the present study, patients who devel-
oped VOD/SOS received a significantly more intensive busul-
fan-based chemotherapy (myeloablative conditioning
regimen), and received more than 20 blood transfusion pre-
HSCT (leading to a liver iron overload) and hepatotoxic drugs
(mainly inotuzumab ozogamicin) (Table 4). These findings
support previous reports [42] and the findings of a recent
expert panel review [43].
The importance of having, along with clinical VOD/SOS
criteria, a radiologic technique able to better identify and dif-
ferentiate VOD/SOS from other clinical complications of HSCT
is well recognized. Thus, our protocol included gray-scale
and color Doppler ultrasound examinations when LSM values
were increased or a diagnosis of VOD/SOS was established.
Indeed, we confirmed that the majority of patients who
developed VOD/SOS met 3 Lassau criteria [18] (Table 5).
Our results support the EBMT and British Committee for
Standards in Haematology/British Society for Blood and Mar-
row Transplantation guidelines [8,12] suggesting that ultra-
sound examination could have a pivotal role as the first
bedside technique for use in the differential diagnosis among
several abdominal post-HSCT complications and to confirm
the VOD/SOS diagnosis in uncertain cases. However, the posi-
tivity of ultrasound signs is consistent with the clinical occur-
rence of VOD/SOS criteria, precluding its use in predicting
diagnosis.
The main finding of this study is that for the first time in a
prospective study of adult HSCT recipients, the increase in LSM
values after HSCT as assessed by TE has been identified as an
accurate predictor of VOD/SOS development. Of note, an LSM
increase after HSCT over the pre-HSCT assessment precedes
the clinical VOD/SOS diagnosis by 2 to 12 days. This increase in
LSM values compared with previous measurements was signif-
icantly associated with the diagnosis of VOD/SOS. Our results
obtained in an adult cohort are consistent with the findings of
our previous study in a pediatric setting [28] using the same
Table 4
VOD/SOS Risk Factors According to EBMT and by VOD/SOS Diagnosis
VOD/SOS Risk Factors Study Population
(n = 78)
Without VOD/SOS
(n = 74; 94.9%)
With VOD/SOS
(n = 4; 5.1%)
P Value*
Transplantation-related factors
Unrelated donor 63 (80.8) 60 (81.1) 3 (75) .582
HLA-mismatched donor 32 (41) 31 (41.9) 1 (25) .640
Non-T cell-depleted transplant 78 (100) 74 (100) 4 (100) 1
Myeloablative conditioning regimen 49 (62.8) 47 (63.5) 2 (50) .625
Oral or high-dose busulfan-based regimen 62 (79.5) 59 (79.7) 3 (75) .609
High-dose TBI-based regimen 3 (3.8) 3 (4.1) 0 (0) .852
Second HSCT 7 (9) 6 (8.1) 1 (25) .319
Patient and disease-related factors
Older age 21 (26.9) 21 (28.4) 0 (0) .569
Karnofsky Performance Status score <90% 0 (0) 0 (0) 0 (0) —
Metabolic syndrome 10 (12.8) 9 (12.2) 1 (25) .429
Female receiving norethisterone 3 (3.8) 3 (4.1) 0 (0) .852
Advanced disease (beyond CR2 or relapsed/ refractory) 23 (29.5) 21 (28.4) 2 (50) .577
Thalassemia 0 (0) 0 (0) 0 (0) —
Genetic factors (eg, GSTM1 polymorphism, C282Y allele,
MTHFR 677CC/1298CC haplotype)
1 (1.3) 1 (1.4) 0 (0) .949
Hepatic-related factors
Transaminases 2.5£ ULN 0 (0) 0 (0) 0 (0) —
Serum bilirubin 1.5£ ULN 1 (1.3) 1 (1.4) 0 (0) .949
Active viral hepatitis 3 (3.8) 3 (4.1) 0 (0) .852
Cirrhosis 0 (0) 0 (0) 0 (0) —
Abdominal or hepatic irradiation 1 (1.3) 1 (1.4) 0 (0) .949
Previous use of inotuzumab ozogamicin 4 (5.1) 1 (1.4) 3 (75) <.00001
Other hepatotoxic drugs 2 (2.6) 1 (1.4) 1 (25) .004
Iron overload 3 (3.8) 1 (1.4) 2 (50) .006
Significant P values are in bold type.
ULN indicates upper limit of normal.
* Wilcoxon rank-sum test/Fisher exact test.
Table 5
US Criteria According to Lassau et al [18] in Patients with VOD/SOS
Criteria Patient 1 Patient 2 Patient 3 Patient 4
Clinical VOD/SOS diagnosis +7 +1 +27 +29
Ultrasound and color Doppler criteria 4 3 8 3
Gray-scale ultrasound morphological criteria, n 4 3 6 2
Hepatomegaly Yes, +7 Yes, +3 Yes, +27 Yes, +26
Splenomegaly None None Yes, +21 None
Gallbladder wall thickening >6 mm Yes, +7 None Yes, +27 None
Portal vein diameter >12 mm Yes, +7 Yes, +7 Yes, +12 Yes, +26
Hepatic vein diameter <3 mm None None None None
Ascites Yes, +7 Yes, +3 Yes, +27 None
Visualization of paraumbilical vein None None Yes, +27 None
Ultrasound color Doppler criteria, n 0 0 2 1
Mean portal flow velocity <10 cm/s or hepatofugal flow None None None None
Flow recorded in paraumbilical vein None None Yes, +27 Yes +26
Monophasic flow or flow recorded in hepatic veins None None None None
Hepatic Artery Resistive Index >.75 —  Yes, +27 None
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results reported by Reddivalla et al [31] using a different ultra-
sound elastography method (ie, acoustic radiation force
impulse), again in a pediatric population.
In addition, in patients who developed VOD/SOS and were
specifically treated, LSM values were reduced within 2 to 4
weeks after diagnosis, reaching pretransplantation values. It
could be argued that these findings, if confirmed in future
studies, could drive the duration of treatment, an issue that
has not yet been addressed in clinical trials.
Finally, LSM was able to discriminate between VOD/SOS
and other post-HSCT complications, enabling a definitive dif-
ferential diagnosis. We have shown that the median LSM
values of patients with VOD/SOS were significantly higher
than those of patients with other therapy-associated livercomplications (eg, acute cholecystitis, cholangitis, DILI
related to antimycotic drugs, hepatic GVHD, isolated liver
biochemical alterations, fulminant Epstein-Barr virus-
related hepatitis reactivation) regardless of CTC grade
(Figure 4). This result is apparently in contrast with the find-
ings of Karlas et al [29], who reported significantly higher
LSM values measured by TE in 5 of 59 HSCT recipients who
developed severe hepatic involvement after HSCT (CTC
grade 4 to 5) compared with the others who did not (mean,
6.2 § 1.5 kPa versus 4.7 § 1.7 kPa). A possible explanation
for this discrepancy is the fact that VOD/SOS was not ana-
lyzed separately but was included in the severe complication
group without any specifications.
However, the predictive role and meaning of pre-HSCT
LSM values in liver complications remains unclear. Even if,
Figure 2. Variation of LSM values at each determination for all patients. The red solid line represents patients who developed VOD/SOS after HSCT; blue solid line,
patients who did not develop VOD/SOS after HSCT; yellow dotted line, patients who developed liver complications other than SOS/VOD.
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that a pre-HSCT LSM cutoff of 8 kPa measured by TE was able
to identify patients developing liver toxicity (defined as bili-
rubin >2 mg/dL) after HSCT. Our present findings and data by
Reddivalla et al [31] do not support the foregoing findings.
Indeed, we observed no significant differences in pre-HSCT
LSM values between patients who developed VOD/SOS and
those who did not.
The present study has several limitations. A relatively
small number of patients with VOD/SOS were included,
although the number was in line with the prevalence of this
disease in adults reported in the literature [1]. The LSM
assessments were scheduled arbitrarily on 3 consecutive
visits (days +9/10, +15/17, and +22/24). Evidence for a stan-
dard LSM assessment schedule is not yet available, and our
schedule was arbitrarily applied owing to the experimental
role of LSM in this setting. A daily LSM assessment, which is
hardly practicable in the actual clinical setting, could iden-
tify the real advantages of TE for assessing LSM. Another
limitation is that in this study, we assessed LSM only by TE,
and thus it is difficult to compare our findings with results
obtained with other ultrasound-based elastography techni-
ques, as demonstrated recently [44]. Nevertheless, even
though a dedicated device is needed, TE is still consideredthe best validated and readily available elastography tech-
nique, and most centers use TE as a standard technique to
assess LSM even in the consolidated hepatologic indications
[38,45,46]. Finally, we excluded patients with pathological
obesity (BMI >40 kg/m2) owing to the technical limitations
of the TE device’ s “M” probe. The use of an “XL” probe [47]
(a dedicated probe for obese patients) or other ultrasound-
based elastography techniques could bypass this technical
limitation.
In conclusion, this prospective study in a large number of
patients resembles a real-life HSCT practice and suggests
that LSM assessment by TE may be a promising technique
for obtaining an early, preclinical diagnosis and predicts
VOD/SOS. In addition, it also may be useful for assessing
treatment response in adult HSCT recipients who develop
VOD/SOS. Moreover, this noninvasive bedside method is
reproducible and well tolerated by patients. In addition, it
provides a standardized quantitative measurement, avoid-
ing the use of radiation and i.v. contrast agents and preclud-
ing the risk of bleeding or infection. LSM as assessed by TE
appears to accurately differentiate between VOD/SOS and
other liver-related HSCT complications. Further multicenter
prospective studies in adult and pediatric settings are
needed to confirm the role of TE assessment of LSM in the
Figure 3. Variation in LSM values after VOD/SOS-specific treatment of patients with VOD/SOS diagnosis.
Figure 4. Boxplot of maximum LSM values after HSCT in patients with VOD/SOS diagnosis by CTC degree.
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elastography techniques.
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